secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001193125-23-039772
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir reports FY2022 net loss of $168.7M and positive Phase 2 posoleucel data in kidney transplant
--------------------------------------------------------------------------------

- FY2022 net loss $168.7M ($2.20/share); R&D spend $118.9M; cash & securities $233.8M as of Dec 31, 2022.
- 2023 operating expense guidance of $150-170M (excl. non-cash); Phase 3 enrollment completion expected by end of 2023 with 2024 data.
- Phase 2 study: posoleucel achieved ≥1-log viral load reduction in 39% vs 14% placebo; biweekly dosing 50%.
- In high viral load (≥10,000 copies/mL): 69% posoleucel vs 25% placebo achieved ≥1-log reduction; 75% for biweekly dosing.
- Posoleucel well tolerated with balanced safety; no GVHD, cytokine release syndrome, or treatment-related acute rejection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/0001193125-23-039772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312523039772/d468482d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-039772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer